Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 4037-4037
    Abstract: Background: MicroRNAs (miRNAs) are a family of small (20- to 24-nucleotide) non-coding RNAs that regulate gene expression at the post-transcriptional level. Although miRNAs are potential prognostic biomarkers in colorectal cancers (CRCs), their value based on the patient race/ethnicity has not been examined. Thus, this study evaluated the prognostic value of miRNAs for CRCs in African-Americans (Blacks) and non-Hispanic Caucasians (Whites). Methods: TaqMan® microRNA assays and qRT-PCR were used to quantify the expression profiles of a panel of miRNAs (miR-20a, miR-21, miR-106a, miR-181b, and miR-203) in CRCs and corresponding benign tissues collected from 104 Blacks and 114 Whites. The expression profiles were correlated with patient overall survival, and p values were calculated by the log-rank test. Results: For both racial groups, all five miRNAs had higher expression in CRCs ( & gt;1.0 fold; range, 1.23 to 7.52) compared to their corresponding controls. Univariate Kaplan-Meier analyses demonstrated that increased expression of miR-106a was associated with decreased overall survival of both Blacks and Whites (p=0.040 and p=0.049, respectively). Increased expressions of miR-181b and miR-203 were each significantly associated with short patient survival of Blacks (p=0.009 and 0.003, respectively), but not Whites (p=0.117 and p=0.071, respectively). When Blacks and Whites were combined, over-expression of miR-21 was associated with poor patient survival (p=0.049), but statistical significance was not reached when the values were analyzed based on race. In contrast, increased expression of miR-20a was not associated with survival of either Blacks (p=0.193), Whites (p=0.242), or the combined patient population (p=0.072). Conclusions: These findings suggest that, for all CRC patients, over-expression of miR-21 and miR-106a are associated with poor prognosis, whereas over-expression of miR-181b and miR-203 are associated with poor outcomes for Blacks. These findings suggest that, in prognostic assessment of miRNAs in CRC, patient race/ethnicity should be considered. These studies were supported by NCI/NIH grants, U54-CA118948 and R01-CA098932-01. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4037.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 19, No. 14 ( 2013-07-15), p. 3955-3965
    Abstract: Purpose: MicroRNAs (miRNA) have potential prognostic value for colorectal cancers; however, their value based on patient race/ethnicity and pathologic stage has not been determined. The goal was to ascertain the prognostic value of 5 miRNAs with increased expression in colorectal cancers of African American (black) and non-Hispanic Caucasian (white) patients. Experimental Design: TaqMan quantitative real-time PCR was used to quantify expression of miR-20a, miR-21, miR-106a, miR-181b, and miR-203 in paired normal and tumor colorectal cancer archival tissues collected from 106 black and 239 white patients. The results were correlated with overall survival based on patient race/ethnicity and pathologic stage. Because decisions about adjuvant therapy are important for stage III colorectal cancers, and because miR-181b seemed to have prognostic value only for stage III black patients, we assessed its prognostic value in a separate cohort of 36 stage III colorectal cancers of blacks. Results: All 5 miRNAs had higher expression in colorectal cancers ( & gt;1.0-fold) than in corresponding normal tissues. High expression of miR-203 was associated with poor survival of whites with stage IV colorectal cancers (HR = 3.00; 95% CI, 1.29–7.53), but in blacks it was an indicator of poor survival of patients with stages I and II colorectal cancers (HR = 5.63; 95% CI, 1.03–30.64). Increased miR-21 expression correlated with poor prognosis for white stage IV patients (HR = 2.50; 95% CI, 1.07–5.83). In both test and validation cohorts, high miR-181b expression correlated with poor survival of only black patients with stage III colorectal cancers (HR = 1.94; 95% CI, 1.03–3.67). Conclusion: These preliminary findings suggest that the prognostic value of miRNAs in colorectal cancers varies with patient race/ethnicity and stage of disease. Clin Cancer Res; 19(14); 3955–65. ©2013 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 4156-4156
    Abstract: Background: Recently, we demonstrated that, for colorectal carcinomas (CRCs), genetic alterations in the rabphillin-3A-like (RPH3AL) gene are associated with aggressive tumor phenotypes and poor patient survival. The mammalian target of rapamycin (mTOR) pathway regulates tumor growth by integrating diverse signals of growth factors, nutrients, and energy sufficiency. Therefore, we determined the effects of wild-type (w+) and mutated (67w-, 175w-, 290w-) RPH3AL on the mTOR signaling pathway in CRC tissues and in a line of colon cancer cells (LoVo). Materials and Methods: Ninety five prospectively collected, frozen CRC tissues and their matching control tissues were analyzed for the mutational status of RPH3AL using the cDNA polymerase chain reaction and direct sequencing. Expression constructs of RPH3AL w+ and the mutant variants were developed using eukaryotic expression vectors. LoVo cells were stably transfected with the w+ and w- forms of RPH3AL. Western blot analyses were performed on lysates of CRC tissues and LoVo cells to assess expression of p53, p27, and PCNA and proteins in the mTOR pathway. Results: Mutational analysis of RPH3AL detected four missense mutations: at codon 67 (Val & gt; Met) in 2 CRCs, at codon 175 (Pro & gt; Ser) in 1 CRC, and at codon 290 (Arg & gt; Lys) in 1 CRC. Western blot analyses demonstrated that over-expression of wt RPH3AL in LoVo cells or CRC tissues with wt RPH3AL led to decreases in total mTOR and to phosphorylation of Rictor p-mTOR (S2481), Raptor p-mTOR (S2448), p70S6K1, and p70S6K. In contrast, in CRC tissues or LoVo cells with over-expression of mutant forms of RPH3AL, there were higher levels of total mTOR and greater phosphorylation of the Rictor, raptor, P70S6K1 and p70S6K. Additionally, CRC w+ RPH3AL and LoVo cells that over-expressed w+ RPH3AL demonstrated higher levels of p27, and lower levels of PCNA, and p53. In contrast, the CRC tissues or LoVo cells with over-expression of RPH3AL mutants exhibited lower levels of p27 and higher levels of PCNA. Conclusion: The results demonstrate that the RPH3AL gene has a tumor-suppressing effect involving changes in the mTOR pathway and suggest that these changes inhibit progression of CRCs. This work was supported by grants from the NCI/NIH (2U54-CA118948-06, R01-CA98932, and R03-CA139629). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4156. doi:1538-7445.AM2012-4156
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Microbiological Methods, Elsevier BV, Vol. 68, No. 1 ( 2007-1), p. 52-59
    Type of Medium: Online Resource
    ISSN: 0167-7012
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2007
    detail.hit.zdb_id: 1483012-7
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 2271-2271
    Abstract: Background: Breast carcinomas (BCs) are more aggressive in African Americans (AAs) than in non-Hispanic Caucasian Americans (NHCAs); the reasons for this difference have not been fully elucidated. We recently demonstrated that single nucleotide polymorphisms (SNPs) at codon 72 of the p53 gene are significantly associated with a worse outcome in AAs with colorectal carcinomas. Therefore, we determined the prevalence of such SNPs in BCs and its possible association with adverse clinical or pathological features of BCs in AAs as well as NHCAs. Methods: To determine the phenotypic status at codon 72, DNA samples, extracted from 137 BCs and their matching benign tissues (from 47 AAs and 90 NHCAs), were analyzed for genotypes by direct sequencing of exon 4. Also, these samples were evaluated for microsatellite (MS) instability by use of the ABI 3100 system. The results obtained were correlated with the demographic and clinicopathological features of the BCs. Results: Overall, SNPs leading to either Arg/Pro or Pro/Pro at codon 72 were observed in 102 of 137 (74%) BCs, with a slightly higher prevalence in AAs compared to NHCAs (39 of 47; 83% vs. 63 of 90; 70%). The most frequent phenotype was Arg/Pro (84 of 137; 61%), followed by Arg/Arg (35 of 137; 26%) and Pro/Pro (18 of 137; 13%). The prevalence of the homozygous Pro/Pro phenotype, known to be associated with aggressive tumor behavior, was higher in AAs compared to NHCAs (19% vs. 10%). BCs with Pro/Pro or Arg/Pro SNPs were significantly more prevalent in grade III tumors (84%) than in grade I and II tumors (60%) (P=0.005); specifically, this distribution was highly significant in AAs (100% vs. 53%; χ2P=0.0001) as compared to NHCAs (72% vs. 62%; χ2P=0.451). Also, in AAs, BCs with the Pro/Pro phenotype were more frequently associated with MS stable status compared to the other phenotypes (63% vs. 18%; χ2P=0.011). Furthermore, Pro/Pro phenotype was associated with a shorter median survival in AAs (39.9 months) compared to NHCAs (112.2 months). Conclusions: These preliminary findings suggest that SNPs at codon 72 of p53 gene are associated with aggressive tumor behavior in AAs. Additionally, the Pro/Pro phenotype is associated with MS stable disease and with a shorter median survival in AAs but not in NHCAs. These studies were supported by the UAB-SPORE grant (a pilot study and a supplement) from NCI/NIH (5P50CA089019) and by the Susan G. Komen Breast Cancer Foundation (POP0601383). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2271. doi:10.1158/1538-7445.AM2011-2271
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Future Medicine Ltd ; 2010
    In:  Biomarkers in Medicine Vol. 4, No. 5 ( 2010-10), p. 761-770
    In: Biomarkers in Medicine, Future Medicine Ltd, Vol. 4, No. 5 ( 2010-10), p. 761-770
    Abstract: miRNAs serve as micromanagers, negatively regulating gene expression. Since altered miRNA expression is implicated in the pathobiology of various cancers, including colorectal cancers (CRCs), these molecules serve as potential therapeutic targets. Manipulation of miRNAs may offer an alternative therapy for chemo- and radio-resistant CRCs. For CRC patients, miRNA expression patterns can be used for diagnosis, and to predict prognosis and efficacy of therapy. This article describes the methodological approaches for miRNA measurement, their function in the pathobiology of CRCs and their potential clinical utility.
    Type of Medium: Online Resource
    ISSN: 1752-0363 , 1752-0371
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2010
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 8_Supplement ( 2011-04-15), p. 1167-1167
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 1167-1167
    Abstract: Background: MicroRNAs (miRNAs) have potential prognostic and therapeutic value in human malignancies, including colorectal cancer (CRC). Many human tumor tissues are available as formalin-fixed paraffin-embedded (FFPE) specimens, which are an excellent source for biomarker discovery. However, the stability of miRNAs and the reliability of measurements of miRNA expression in archival samples stored for long periods of time ( & gt; 20 years) are not known. Therefore, we evaluated the stability and expression levels of miRNAs in FFPE CRC specimens and compared their expression levels to those in CRC cell lines. Methods: A panel of seven miRNAs (RNU6B, miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p) in 219 CRC archival tissue samples, stored for 6 to 28 years (1982 through 2004) in a dark, cool place, and 11 CRC cell lines (LoVo, HCT116, HCT116 (p53-/-), RKO, LS174T, CaCo-2, Colo205, SW480, WiDr, HCT-15, and DLD-1) were evaluated by the use of TaqMan® microRNA assays and by quantitative real-time polymerase chain reactions. In CRCs, these miRNAs, excluding RNU6B (an endogenous reference molecule), are candidate prognostic or predictive biomarkers. All assay reagents used were from Applied Biosystems Inc., (Carlsbad, CA). From each block, tissue sections, 10-microns thick, were used for extraction of miRNAs. miRNA expression was measured as threshold cycle (Ct) values. Triplicate reactions were averaged for each miRNA, and the raw Ct values were determined. The Kruskal-Wallis one-way analysis of variance was employed to analyze the miRNA expression difference among archived samples from different years. Correlation coefficient analysis was performed to compare the expression levels of miRNA in archival tissues and cell lines. Results: In both CRC archival tissues and cell lines, the median Ct values of all miRNAs ranged from 19 to 32. All seven miRNAs were stable in CRC tissues stored for up to 28 years; their expression levels were similar across all ages of blocks. (Kruskall-Wallis P values for all 7 miRNAs ranged from 0.627 to 1.000.) There was good correlation between the levels of expression of all seven miRNAs in FFPE tissues and in the CRC cell lines (correlation coefficient R2 range, 0.784 to 0.937). Conclusions: Since miRNAs are stable in archival CRC samples stored for over 20 years, FFPE samples can be used to evaluate miRNAs as biomarkers. These studies were supported by grants 2U54-CA118948-03, R01-CA98932, and R03-CA139629 from the NCI/NIH. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1167. doi:10.1158/1538-7445.AM2011-1167
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 1944-1944
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 1944-1944
    Abstract: Background: microRNAs (miRNAs) are 19 to 24 nucleotide sequences that regulate cell proliferation, differentiation, and apoptosis. miRNA-181b is involved in tumor initiation and progression of several human malignancies including colorectal cancers (CRCs). Thus, we sought to determine the prognostic value of miRNA-181b in CRCs. Methods: Expression of miRNA-181b was quantified, by quantitative PCR (q-RT-PCR), in normal (benign colonic epithelia) tissues and in their corresponding CRC archival tissue samples collected from 345 patients. The expression levels were correlated with patient overall survival. Putative molecular targets of miRNA-181b were identified by in silico analysis. miRNA-181b mediated, post-transcriptional regulation of these targets was assessed in CRC cell lines (SW480, HCT116 p53-/- and HCT116 +/+) by transfection studies. The targets were validated by measuring their mRNA expression levels, by use of qRT-PCR, in CRC tissues that exhibited elevated levels of miRNA-181b as well as by cloning techniques to assess a direct interaction between miRNA-181b and 3’UTRs of its target genes using luciferase assays. Results: Survival analysis indicated that increased expression of miRNA-181b was associated with poor prognosis for CRCs (log rank, p=0.004). Fourteen putative molecular targets of miRNA-181b were identified by in silico analysis, and miRNA-181b mediated post-transcriptional regulation of these targets was validated in CRC cell lines by q-RT-PCR. Integrin alpha-3 was up-regulated, and BCL2LII and TNFα were down-regulated upon overexpression of miRNA-181b in vitro. Also, these targets were validated in CRC tissues that exhibited elevated miRNA-181b levels. The direct interaction of miRNA-181b with the target gene 3’UTRs was validated with luciferase assays. Conclusions: These findings demonstrate that miRNA-181b regulates expression of Integrin alpha-3, BCL2LII, and TNFα; and is a prognostic marker for colorectal cancers. Citation Format: Liselle Bovell, Balananda-Dhurjati K. Putcha, Divya Devadasan, Sejong Bae, William E. Grizzle, Upender Manne. Evaluation of the prognostic value of miRNA-181b and its target identification and validation in colorectal cancers. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1944. doi:10.1158/1538-7445.AM2013-1944
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: PLOS ONE, Public Library of Science (PLoS), Vol. 10, No. 6 ( 2015-6-12), p. e0129216-
    Type of Medium: Online Resource
    ISSN: 1932-6203
    Language: English
    Publisher: Public Library of Science (PLoS)
    Publication Date: 2015
    detail.hit.zdb_id: 2267670-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 23, No. 11_Supplement ( 2014-11-01), p. C22-C22
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 23, No. 11_Supplement ( 2014-11-01), p. C22-C22
    Abstract: Background: MicroRNAs (miRs) are 19 to 24 nucleotide sequences that regulate cell proliferation, differentiation, and apoptosis. mir-181b is involved in tumor initiation and progression of several human malignancies, including colorectal cancers (CRCs). Our recent study of CRCs has demonstrated that increased expression of miR-181b is an indicator of poor patient prognosis, especially for African American patients with Stage III CRCs [Clin Cancer Res; 19(14); 1–11. 2013]. In the current study, we investigated molecular mechanisms of miR-181b over-expression in aggressive progression of CRCs. Methods: The effects of miR-181b over-expression on cell migration, apoptosis, and the cell cycle were analyzed. Putative molecular targets of miR-181b were identified by in silico analysis. miR-181b mediated, post-transcriptional regulation of these targets was assessed in CRC cell lines (HCT116wt/wt, HCT116 p53-/- and SW480 p53mut/mut) subjected to transient transfection. The targets were validated by measuring their mRNA expression levels, by qRT-PCR, in Stage III CRC tissues (n=18), which exhibited elevated levels of miR-181b. Further, luciferase assays were performed to assess a direct interaction between miR-181b and the 3′UTR of its target genes. Results: Transfection studies indicated that, in CRC cells, over-expression of miR-181b enhanced the rate of migration, diminished apoptosis, and shifted CRC cells from the G1 to the G2/M phase in a p53-dependent manner. Fourteen putative molecular targets of miR-181b were identified by in silico analysis, and miR-181b mediated post-transcriptional regulation of these targets was validated in CRC cell lines by qRT-PCR. Upon over-expression of miR-181b, integrin alpha-3 (cell surface adhesion molecule that mediates cell-adhesion to extra cellular matrix) was up-regulated, and BCL2L11 (apoptosis facilitator) and TNF-alpha (cytokine that has been implicated in tumor regression and also causes apoptosis) were down-regulated. Also, these targets were validated in human CRC tissues that exhibited elevated miR-181b levels (n=8). Finally, the direct interaction of miR-181b with the target gene 3′UTRs was confirmed by luciferase assays. Conclusions: These results demonstrate that, in CRCs, miR-181b post-transcriptionally regulates expression of integrin alpha-3, BCL2L11, and TNF-alpha and also regulates the cell cycle, migration, and apoptosis. This study was funded in part by the National Cancer Institute of the National Institute of Health UAB/TU/MSM Partnership grant (U54 CA118948). Citation Format: Balananda-Dhurjati Kumar Putcha, Brittany Michelle Holt, Liselle Bovell, Trafina Jadhav, Upender Manne. Overexpression of miR-181b and underlying molecular mechanisms in aggressive progression of African American colorectal cancers. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C22. doi:10.1158/1538-7755.DISP13-C22
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages